The increase in ROP requiring treatment during 2019 is not attributable to the changes in antibiotic use; rather, it may be due to a change of the indications of ROP treatment with the new anti-vascular endothelial growth factor. This evidence concerns the gene VEGFA and retinopathy of prematurity.